Erratum: Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM) (Modern Rheumatology (2007) vol. 17 (28-32) 10.1007/s10165-006-0532-0);Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM)

Modern Rheumatology

Volumn 17, Issue 1, 2007, Pages 28-32

  Yamanaka, Hisashi ^a   Tanaka, Yoshiya ^b   Sekiguchi, Naoya ^c   Inoue, Eisuke ^a   Saito, Kazuyoshi ^b   Kameda, Hideto ^c   Iikuni, Noriko ^a   Nawata, Masao ^b   Amano, Kouichi ^c   Shinozaki, Mikiko ^a   Takeuchi, Tsutomu ^c  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

EULAR response; Infliximab; Retrospective study; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR;

ADULT; AGE; ARTICLE; CLINICAL STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; JOINT SWELLING; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; REMISSION; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33947384138     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-007-0562-2     Document Type: Erratum

References (14)

1. GS Firestein 2003 Evolving concepts of rheumatoid arthritis Nature 423 356-61 12748655 10.1038/nature01661 1:CAS:528:DC%2BD3sXjs1ynu7c%3D
2. JR Kalden 2002 Expanding role of biologic agents in rheumatoid arthritis J Rheumatol Suppl 66 27-37 12435166 1:CAS:528:DC%2BD38XptVGnsLk%3D
3. AL Weaver 2004 Efficacy and safety of the anti-TNF biologic agents Modern Rheum 14 2 101-12 1:CAS:528:DC%2BD2cXlt1Glu74%3D
4. AJ Ostor 2005 Beyond methotrexate: Biologic therapy in rheumatoid arthritis Clin Med 5 3 222-6 16011212
5. R Maini EW St Clair F Breedveld D Furst J Kalden M Weisman 1999 Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial Lancet 354 1932-9 10622295 10.1016/S0140-6736(99)05246-0 1:CAS:528:DC%2BD3cXit1Oquw%3D%3D
6. PE Lipsky DM van der Heijde EW St Clair DE Furst FC Breedveld JR Kalden 2000 Infliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 343 1594-602 11096166 10.1056/NEJM200011303432202 1:CAS:528:DC%2BD3cXovVeltLk%3D
7. RN Maini FC Breedveld JR Kalden JS Smolen D Furst MH Weisman 2004 Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate Arthritis Rheum 50 1051-65 15077287 10.1002/art.20159 1:CAS:528:DC%2BD2cXjslGqsrk%3D
8. N Miyasaka T Takeuchi K Eguchi 2005 Official Japanese Guidelines for the use of infliximab for rheumatoid arthritis Modern Rheum 15 1 4-8 10.1007/ s10165-004-0357-7 1:CAS:528:DC%2BD2MXhsV2is7k%3D
9. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of DAS28-ESR and DAS28-CRP on threshold values. Ann Rheum Dis 2006; in press [Epub ahead of print]
10. PL van Riel AM van Gestel LB van de Putte 1996 Development and validation of response criteria in rheumatoid arthritis: Steps towards an international consensus on prognostic markers Br. J Rheumatol 35 Suppl 2 4-7 8810683
11. T Takeuchi M Togo A Etoh T Suzuki PA Callegari KE Gilmer 2006 Safety of infliximab therapy in 4,475 Japanese patients with rheumatoid arthritis: results from post marketing surveillance study (Abstract) Ann Rheum Dis 65 Suppl II 503
12. EW St Clair DM van der Heijde JS Smolen RN Maini JM Bathon P Emery 2004 Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial Arthritis Rheum 50 3432-43 15529377 10.1002/art.20568 1:CAS:528:DC%2BD2cXhtVOqtrvJ
13. L Klareskog D van der Heijde JP de Jager 2004 TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial Lancet 363 9410 675-81 15001324 10.1016/S0140-6736(04)15640-7 1:CAS:528:DC%2BD2cXhs12jur4%3D
14. JJ Anderson G Wells AC Verhoeven DT Felson 2000 Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration Arthritis Rheum 43 1 22-9 10643696 10.1002/ 1529-0131(200001)43:22::AID-ANR43.0.CO;2-9 1:STN:280:DC%2BD3c7gs1Cqsg%3D%3D